Incidence of cardiovascular disease in patients with familial hypercholesterolemia phenotype: analysis of 5 years follow-up of real-world data from more than 1.5 million patients

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Masana, Luís
• dc.contributor.author Zamora, Alberto
• dc.contributor.author Plana, Nuria
• dc.contributor.author Comas Cufí, Marc
• dc.contributor.author Garcıa-Gil, Maria
• dc.contributor.author Martí, Ruth
• dc.contributor.author Ponjoan, Anna
• dc.contributor.author Alves-Cabratosa, Lia
• dc.contributor.author Elosua Llanos, Roberto
• dc.contributor.author Marrugat de la Iglesia, Jaume
• dc.contributor.author Dégano, Irene R.
• dc.contributor.author Ramos, Rafel
• dc.date.accessioned 2020-02-10T08:22:29Z
• dc.date.available 2020-02-10T08:22:29Z
• dc.date.issued 2019
• dc.description.abstract In the statin era, the incidence of atherosclerotic cardiovascular diseases (ASCVD) in patients with familial hypercholesterolemia (FH) has not been updated. We aimed to determine the incidence of ASCVD in patients with FH-phenotype (FH-P) and to compare it with that of normal low-density lipoprotein cholesterol (LDL-C) patients. We performed a retrospective cohort study using the Database of the Catalan primary care system, including ≥18-year-old patients with an LDL-C measurement. From 1,589,264 patients available before 2009, 12,823 fulfilled FH-P criteria and 514,176 patients were normolipidemic (LDL-C < 115 mg/dL). In primary prevention, patients with FH-P had incidences of ASCVD and coronary heart disease (CHD) of 14.9/1000 and 5.8/1000 person-years, respectively, compared to 7.1/1000 and 2.1/1000 person-years in the normolipidemic group. FH-P showed hazard ratio (HR) of 7.1 and 16.7 for ASCVD and CHD, respectively, in patients younger than 35 years. In secondary prevention, patients with FH-P had incidences of ASCVD and CHD of 89.7/1000 and 34.5/1000 person-years, respectively, compared to 90.9/1000 and 28.2/1000 person-years in the normolipidemic group (HR in patients younger than 35 years: 2.4 and 6.0). In the statin era, FH-P remains associated with high cardiovascular risk, compared with the normolipidemic population. This excess of risk is markedly high in young individuals.
• dc.format.mimetype application/pdf
• dc.identifier.citation Masana L, Zamora A, Plana N, Comas-Cufí M, Garcia-Gil M, Martí R.et al. Incidence of cardiovascular disease in patients with familial hypercholesterolemia phenotype: analysis of 5 years follow-up of real-world data from more than 1.5 million patients. J Clin Med. 2019 Jul 23;8(7):1080. DOI: 10.3390/jcm8071080
• dc.identifier.doi http://dx.doi.org/10.3390/jcm8071080
• dc.identifier.issn 2077-0383
• dc.identifier.uri http://hdl.handle.net/10230/43533
• dc.language.iso eng
• dc.publisher MDPI
• dc.rights Copyright © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Familial Hypercholesterolemia
• dc.subject.keyword Atherosclerosis
• dc.subject.keyword Cardiovascular diseases
• dc.subject.keyword Incidence
• dc.subject.keyword Prevention
• dc.subject.keyword Real-world data
• dc.subject.keyword Risk assessment
• dc.title Incidence of cardiovascular disease in patients with familial hypercholesterolemia phenotype: analysis of 5 years follow-up of real-world data from more than 1.5 million patients
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion